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Breast cancer is the leading cause of cancer-related deaths in women due to distinct cancer subtypes associ-
ated with early recurrence and aggressive metastatic progression. High lipoprotein-associated phospholipase
A2 (PLA2G7) expression has previously been associated with aggressive disease and metastasis in prostate
cancer. Here, we explore the expression pattern and functional role of PLA2G7 in breast cancer. First, a bioin-
formatic analysis of genome-wide gene expression data from 970 breast samples was carried out to evaluate
the expression pattern of PLA2G7 mRNA in breast cancer. Second, the expression profile of PLA2G7 was stud-
ied in 1042 breast cancer samples including 89 matched lymph node metastasis samples using immunohisto-
chemistry. Third, the effect of PLA2G7 silencing on genome-wide gene expression profile was studied and
validated in cultured breast cancer cells expressing PLA2G7 at high level. Last, the expression pattern of
PLA2G7 mRNA was investigated in 24 nonmalignant tissue samples and 65 primary and 7 metastatic tumour
samples derived from various organs using qRT-PCR. The results from clinical breast cancer samples indicated
that PLA2G7 is overexpressed in a subset of breast cancer samples compared to its expression in benign breast
tissue samples and that high PLA2G7 expression associated with hormone receptor negativity as well as with
poor prognosis in a subset of breast cancer samples. In vitro functional studies highlighted the putative role
of PLA2G7 in the regulation of epithelial-mesenchymal transition (EMT)-related signalling pathways, vimentin
and E-cadherin protein expression as well as cell migration in cultured breast cancer cells. Furthermore, sup-
porting the findings in breast and prostate cancer, high PLA2G7 mRNA expression was associated with meta-
static cancer in four additional organs of origin. In conclusion, our results indicate that PLA2G7 is highly
expressed in a subset of metastatic and aggressive breast cancers and in metastatic samples of various tissues
of origin and promotes EMT and migration in cultured breast cancer cells.
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Introduction
Breast cancer is the most frequent cancer in women
worldwide accounting for 25% of all cancer cases
among females [1]. Although survival rates of breast
cancer patients have improved significantly during
the last decade breast cancer is still the leading cause
of cancer-related deaths in women due to distinct
subtypes of breast cancer that are associated with
early recurrence and an aggressive metastatic pro-
gression of the disease [1–4]. Identification of bio-
markers and development of targeted therapies
especially for these malignant tumours is important.
Recently, the regulators of metastasis initiating
epithelial-mesenchymal transition (EMT) have been
suggested as important factors and possible diagnos-
tic markers for aggressive and metastatic breast can-
cers, including triple negative breast cancers (TNBC)
[5–9].
EMT, a vital process during embryogenesis and tis-
sue repair, is characterised by specific gene expression
changes, reduced intercellular adhesion, gain of mes-
enchymal characteristics and increased cell mobility to
distant locations. Loss of immotile epithelial pheno-
type and gain of mesenchymal properties via EMT has
recently been shown to be a key metastasis-promoting
step in many cancers [10]. In addition to enabling
metastasis EMT has been suggested to promote the
generation and function of cancer stem cells as well as
development of drug resistance [11]. EMT is induced
by multiple oncogenic events and signalling pathways
and requires the expression of a variety of regulators,
including members of the Twist, Snail/Slug and Zeb
transcription factor families. In addition, Tiwari et al.
recently reported the SOX4-EZH2 pathway as one of
the master regulators of EMT in metastatic breast can-
cer [12]. Two major hallmarks of EMT are the loss of
expression of the epithelial cell adhesion molecule E-
cadherin (CDH1) and gain of expression of the major
mesenchymal cell cytoskeletal component vimentin
(VIM). The cytoplasmic intermediate filament protein
vimentin is a component of the cytoskeleton normally
found in embryonic or mesenchymal cells. However,
in cancer vimentin is a marker of EMT and is
expressed in neoplastic epithelial cells with metastatic
properties [13–15]. The expression of vimentin corre-
lates with invasiveness and poor prognosis in clinical
cancer samples [16–18].
PLA2G7, also known as lipoprotein-associated phos-
pholipase A2 or platelet-activating factor (PAF) acetyl
hydrolase, is a phospholipase that hydrolyses PAF and
truncated phospholipids generated by oxidative attack
[19]. PLA2G7 was recently reported as a novel
biomarker in 50% of primary and 70% of metastatic
prostate cancers and associated with aggressive disease
in prostate cancer [20]. Furthermore, PLA2G7 was
identified as a potential drug target especially in ERG
oncogene positive prostate cancers and the alterations
induced by PLA2G7 silencing highlighted the potential
of PLA2G7 inhibition as an anti-proliferative, pro-apo-
ptotic and anti-migratory therapeutic approach [20,21].
Interestingly, in addition to ERG oncogene expressing
prostate cancers, high PLA2G7 expression has also
been proposed to play a causal role in colon tumouri-
genesis downstream of loss-of-function TP53 muta-
tions and activating RAS mutations [22]. Supporting
this finding, deletion of PLA2G7 in ApcMin/1 mice has
been shown to decrease both intestinal polyposis as
well as colon tumourigenesis [23]. In recent years,
PLA2G7 has also been under intensive research in the
area of cardiovascular diseases. High PLA2G7 amount
and enzyme activity have been associated with an
increased risk of cardiovascular disease, and PLA2G7
inhibitor darapladib has been studied in the prevention
and treatment of coronary heart disease [24–29].
In this study, we focus on analysing the expression
pattern of PLA2G7 in breast cancer and investigate
the functional role of PLA2G7 in cultured breast can-
cer cells using genome-wide gene expression analy-
sis, immunohistochemistry and functional assays. The
results indicate a role for PLA2G7 in the regulation
of metastasis-enabling EMT and cell migration, asso-
ciate high PLA2G7 mRNA expression with hormone
receptor negative aggressive disease and indicate that
high PLA2G7 protein expression in lymph node
metastases associates with unfavourable prognosis in
breast cancer.
Methods
Transcriptomics analysis
In order to evaluate the in vivo relevance of PLA2G7
in breast cancer, we analysed PLA2G7 mRNA exp-
ression levels in normal (n5 13) and malignant
(n5 957) breast tissue samples using GeneSapiens
database (www.genesapiens.org) [30]. Survival infor-
mation was available for 395 and recurrence data for
159 breast cancer samples.
Clinical material
Breast tumour samples were obtained from patients
at Hamburg University Medical Centre (Hamburg,
Germany) between 1999 and 2007 and Tampere Uni-
versity Hospital (Tampere, Finland) between 1990 and
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1999. Patient data and tumour characteristics have
been described previously [31,32]. Informed consent
for the scientific use of tissue materials was obtained
from the patients and ethical permission was obtained
from the local ethical committees. All procedures were
in accordance with the Helsinki Declaration.
The patient records contained information on clini-
copathological parameters, primary treatments, site
and time of tumour recurrences and survival. The max-
imum follow-up period was 19.8 years. Relapse–free
survival was defined as time to any disease recurrence
(local, regional or distant). The end point in breast can-
cer specific survival was death from breast cancer and
in overall survival death from any cause.
Immunohistochemistry
The construction of tissue microarrays (TMA) has
been described previously [31,32]. The paraffin
embedded breast cancer TMAs containing in total
1042 samples from 897 breast cancer patients, in-
cluding 89 cases with matched primary and lymph
node metastatic samples, were stained with PLA2G7
(1:150, rabbit polyclonal, Cayman Chemical) anti-
body. Immunostaining was performed with the auto-
mated immunostaining device BenchMark XT
(Roche Diagnostics/Ventana Medical Systems, Tuc-
son, AZ, USA) using ultraView Universal DAB
Detection Kit (Roche Diagnostics/Ventana Medical
Systems). PLA2G7 protein expression level in the
epithelial breast cancer cells in each sample was
evaluated independently in blinded fashion by two
pathologists and graded into two groups based on
staining intensity: low expression (no staining or
weak staining), high expression (moderate or strong
staining). After excluding the cases without residual
tissue or tumour cells, 618 breast tumours and 65
lymph node metastasis samples remained eligible for
evaluation.
Cell culture
The breast carcinoma cell lines MDA-MB-468,
MCF-7, MDA-MB-231 and ZR-75-1 cell lines were
from American Type Culture Collection (Manassas,
VA, USA). BT-549 and KPL-1 cell lines were from
Cell Lines Service (Eppelheim, Germany). All cell
lines were maintained according to the distributor’s
instructions.
Gene silencing
For transient knockdown of PLA2G7, siRNA
(SI00072177; siPLA2G7, Qiagen, Valencia, CA) was
transfected into MDA-MB-468 cells using siLentFect
Lipid Reagent (Bio-Rad Laboratories, CA) in Opti-
MEM (Invitrogen, Carlsbad, CA) at a final concentra-
tion of 13 nM. Cells were incubated for 48 hours before
further experiments. To generate stable PLA2G7 defi-
cient MDA-MB-468 cells (MDA-468/PLA2G7- cells),
two lentiviral shRNA constructs (NM_005084.2-
1046s1c1; shPLA2G7_1 and NM_005084.2-684s1c1;
shPLA2G7_2, Sigma-Aldrich, St. Louis, MO) were
transduced into MDA-MB-468 cells as described [33].
All Stars scrambled siRNA (siScr, Qiagen) and non-
targeting construct (SHC002V; shScr: Sigma-Aldrich)
were used as negative control.
Quantitative RT-PCR
The confirmation of effective target gene silencing
was performed with Taqman reverse transcriptase
PCR (qRT-PCR). Total RNA from 70 000 cells was
extracted using RNeasy kit (Qiagen) according to the
manufacturer’s protocol and processed to cDNA with
Applied Biosystems cDNA synthesis kit. TaqMan
gene expression probes and primers from the
Universal Probe Library (Roche Diagnostics, Espoo,
Finland) were used to study PLA2G7 (forward:
tggctctaccttagaaccctga; reverse: ttttgctctttgc cgtacct),
and b-actin (ACTB, forward: ccaaccgcgagaagatga;
reverse: ccagaggcgtacagggatag) mRNA expression.
The quantitative PCR was done using ABI Prism
7900 (Applied Biosystems, Foster City, CA). Quanti-
tation was carried out using the DDCT method with
RQ manager 1.2 software (Applied Biosystems).
Average expression of the control samples was con-
sidered for the calculation of the fold changes and b-
actin was used as an endogenous control. Three or
more replicate samples were studied for detection of
mRNA expression.
Gene expression analysis using bead arrays
500 ng of total purified RNA was used for amplifica-
tion with Illumina RNA TotalPrep Amplification kit
(Ambion, Austin, TX), and biotin labelled cRNA was
hybridised to Sentrix HumanRef-12 vs.3 Expression
Bead Chips (Illumina, San Diego, CA). Analysis was
done as described [20]. Microarray data are available
in the ArrayExpress database (www.ebi.ac.uk/array
express, siRNA treatment: E-MTAB-5397 and
shRNA treatments: E-MTAB-5398). Two replicate
samples were studied for each treatment and gene
expression profiles of the PLA2G7 silenced samples
were compared with the scrambled control-treated
samples. Ingenuity Pathway Analysis (IPA) Software
(Ingenuity Systems Inc., Redwood City, CA, USA),
DAVID Bioinformatics Resources [34,35] and
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Molecular Signatures Database (MSigDB) Gene Set
Enrichment Analysis Software [36,37] were used to
assess the enrichment of functional and pathway
annotations as well as gene sets for the genes dif-
ferentially expressed by PLA2G7 siRNA or both
PLA2G7 shRNAs.
Cell viability and apoptosis assays
The effects of PLA2G7 silencing on cancer cell viabil-
ity and induction of apoptosis were assessed with the
CellTitre-Glo cell viability assay and ApoONE apopto-
sis assay (Promega Inc, Madison, WI, USA) according
to the manufacturer’s instructions. The EnVision mul-
tilabel plate reader (Perkin-Elmer, Waltham, MA) was
used for signal quantification. Scrambled siRNA or
shRNA was used as the negative control and KIF11
siRNA as the positive control.
Western blotting
Western blot analysis was performed using antibodies
against vimentin (1:1000, V6630, Sigma-Aldrich), E-
cadherin (1:1000, Cell Signalling Technology, Dan-
vers, MA), EGFR (1:100, Cell Signalling Technolo-
gies) and b-actin (1:5000, Sigma-Aldrich). The
signals obtained were visualised with the enhanced
chemiluminescence (ECL) detection system (Amer-
sham) and normalised to b-actin signal.
Immunofluorescence staining
For the immunofluorescence staining, MDA-468/
PLA2G7- cells were fixed with 4% paraformaldehyde
(PFA) in PBS, permeabilised with 0.2% Triton X-
100, and blocked with 3% bovine serum albumin in
PBS. Cells were stained with vimentin antibody and
Alexa-conjugated secondary antibody was used for
secondary staining (1:300 dilution; Molecular Probes,
Thermo Fisher Scientific, Waltham, MA, USA).
Nuclei were stained with Vectashield mounting
medium (Vector Laboratories, Burlingame, CA) con-
taining DAPI. Images were taken with Zeiss Axiovert
200M fluorescence microscope (Carl Zeiss AG,
Oberkochen, Germany).
Wound healing invasion assay
MDA-468/PLA2G7- cells were utilized in the
wound healing invasion assay using the IncuCyte
real-time imaging system (Essen BioScience, Ann
Arbor, Michigan, USA). The cells were plated on
96-well plates (ImageLock plate, Essen BioScience,
MI) coated with 50 ml 10% Growth Factor Reduced
Matrigel (BD Biosciences) after which the cells
were allowed to attach overnight at 1378C. A
wound was scratched across each well (Wound
Maker, Essen BioScience) and the growth medium
was removed. The cells were then carefully covered
with 50 ml 25% Matrigel in normal growth medium
and incubated in 378C for 2–3 hours to allow gel-
ling, after which 100 ml of growth medium was
carefully added to each well. The rate of invasion
(wound closure through the matrix) was monitored
hourly with Incucyte imaging software (Essen Bio-
Science) for 72 hours. Invasion efficiency was deter-
mined as percentage of the relative wound
confluence compared to respective negative control
(regarded as 100%).
cDNA tumour panel
TissueScanTM Cancer Survey cDNA Array 96 – I
(Origene, Rockville, MD, USA) consisting of 96
samples from 65 primary and 7 metastatic tumour
samples as well as 24 non-malignant tissue samples
derived from 8 different primary organs and provided
with clinical information was utilised according to
the manufacturer’s instructions to analyse the expres-
sion pattern of PLA2G7 mRNA in multiple malignan-
cies. The expression of PLA2G7 was quantified using
qRT-PCR.
Statistical analysis
Statistical analysis of immunohistochemical samples
was carried out using the SPSS program (SPSS Inc.,
Chicago, IL). Comparisons between categorical varia-
bles were performed using the v2test. Kaplan-Meier
curves were used to estimate survival probability and
patient survival differences were analysed by a log-
rank test. Other statistical analyses were perfor-
med using Student’s t-test (*p <0.05; **p <0.01;
***p <0.001) and the Pearson correlation coefficient.
The results from cultured cells are presented as the
mean6 SD of at least three replicates unless other-
wise stated.
Results
Correlation of PLA2G7 mRNA expression with
hormone receptor expression and prognosis
in breast cancer
To evaluate the expression pattern and possible asso-
ciation of PLA2G7 with poor survival in breast can-
cer, the GeneSapiens database was utilised to analyse
PLA2G7 mRNA expression in 13 normal breast
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samples and 957 breast cancer samples [30]. Com-
parison of PLA2G7 expression levels in normal
breast tissues and breast cancer samples indicated
high PLA2G7 mRNA expression in a subset of breast
cancers (Figure 1A). Co-expression analysis indicated
PLA2G7 mRNA to be overexpressed especially in
breast cancer samples with low oestrogen and proges-
terone receptor (ESR1 and PGR) expression (p5 0
and p5 3.4E-10, respectively; Figure 1B) whereas
the association between high PLA2G7 mRNA and
low HER2/ERBB2 expression was not statistically
significant (supplementary material, Figure S1). To
investigate whether PLA2G7 may have prognostic
significance, Kaplan–Meier analysis was performed.
The results revealed a significant association between
high PLA2G7 mRNA expression and poor breast can-
cer survival (p5 0.004) as well as increased risk of
disease relapse (p5 0; Figure 1C).
To validate the association between high PLA2G7
expression and hormone receptor negativity as well
as poor prognosis in breast cancer, two additional
independent sets of clinical breast cancer tissue
microarrays were studied with immunohistochemical
staining. PLA2G7 expression was analysed in a total
of 683 breast cancer samples, including 65 samples
derived from lymph node metastases (Figure 2A).
High PLA2G7 expression was detected in 21.7%
(n5 148) of all breast cancer samples. Association
between high PLA2G7 expression and standard clini-
copathological parameters is presented in Table 1. In
accordance with the results from bioinformatic analy-
sis of PLA2G7 mRNA expression, high PLA2G7
expression showed significant association with hor-
mone receptor negativity in primary the breast cancer
samples analysed. Furthermore, even though no sig-
nificant association with survival or relapse was seen
in the samples obtained from primary tumours, high
PLA2G7 protein expression was associated with poor
Figure 1.
Figure 1. High PLA2G7 mRNA expression is associated with hor-
mone receptor negativity and poor prognosis in clinical breast
cancer samples. (A) Box plot analysis of normalized PLA2G7
mRNA expression values in normal and malignant tissues. The
box refers to quartile distribution (25–75%) range, with the
median shown as a vertical line. Data observations which lie
more than 1.5*inter-quartile range higher than third quartile are
considered as outliers and indicated separately. (B) The mRNA
co-expression pattern of PLA2G7 and oestrogen receptor (ESR1)
or progesterone receptor (PGR) in breast cancer samples
(n5 957). (C) Kaplan-Meier plot of breast cancer specific sur-
vival and risk of relapse based on PLA2G7 mRNA expression in
breast cancer. A log-rank test was performed between samples
with high (50%) and low (50%) expression to evaluate the
prognostic significance of PLA2G7 mRNA expression level.
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Figure 2. PLA2G7 is expressed in a subset of breast cancers and associates with poor prognosis in breast cancer lymph node metas-
tasis samples. (A) Staining intensity of PLA2G7 in primary breast cancer and breast cancer lymph node metastasis was scored as fol-
lows: Low expression (0 or 1), high expression (11 to 111). Representative section of staining intensities is presented. The areas
presented at higher magnification have been indicated in the core images. (B) Kaplan-Meier curve presentation of overall survival
and risk of relapse in the patient groups with no or weak PLA2G7 staining (n5 57) or positive PLA2G7 staining (n5 8) in the lymph
node metastasis samples.
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survival (p5 0.002) as well as increased risk of dis-
ease relapse (p5 0.005) in the samples obtained from
lymph node metastases (Figure 2B).
No significant difference was detected in PLA2G7
expression between the paired primary tumour and
metastasis samples. A staining result was obtained
for 39 paired primary tumours and lymph node
metastases and 72% (28) of the pairs showed similar
staining intensity in primary and metastatic samples.
PLA2G7 mRNA expression in cultured breast
cancer cells
In order to find a suitable breast cancer cell model
for functional experiments the mRNA expression
level of PLA2G7 was studied in six breast cancer cell
lines with qRT-PCR. Three of the cell lines studied
were ER-positive (MCF-7, KPL-1 and ZR-75-1) and
three were ER-negative (MDA-MB-231, BT-549 and
MDA-MB-468). The results from qRT-PCR analysis
are in accordance with the clinical data and show
high PLA2G7 expression in two hormone receptor
negative cell lines, MDA-MB-468 and BT-549 (Fig-
ure 3A).
The effect of PLA2G7 silencing on genome-wide
gene expression in MDA-MB-468 breast
cancer cells
To investigate the molecular processes regulated by
PLA2G7 in breast cancer cells, the effect of PLA2G7
silencing on genome-wide gene expression profile
was studied in MDA-MB-468 cells expressing
PLA2G7 at high level. The gene expression analysis
was conducted using one siRNA and two different
shRNA molecules silencing PLA2G7 efficiently com-
pared to the respective scrambled control (Figure 3B
and supplementary material, Figure S2A). For MDA-
468/PLA2G7- cells the genes uniformly differentially
regulated by both of the shRNAs were selected for
further analysis.
DAVID Bioinformatics Resources and Ingenuity
Pathway Analysis (IPA) software was used to assess
enrichment of functional and pathway annotations for
Table 1. PLA2G7 expression and standard clinicopathological parameters in 618 breast cancer samples.
TMA 1 TMA 2 (primary tumours)
Variable All (n) All (%)
High PLA2G7
(n)
High PLA2G7
(%) p All (n) All (%)
High PLA2G7
(n)
High PLA2G7
(%) p
All samples 400 100 84 21.0 218 100 56 25.7
Tumour type 309 218
ILC 135 43.7 21 15.6 0.028 27 12.4 5 18.5 0.048
IDC 174 56.3 45 25.9 165 75.7 43 26.1
Hormone receptor status 328 218
negative 53 16.2 16 30.2 0.041 44 20.2 18 40.9 0.010
positive 275 83.8 51 18.0 174 79.8 38 21.8
HER2 expression 330 187
negative 285 86.4 54 18.9 0.061 160 85.6 41 25.6 0.706
positive 45 13.6 14 31.1 27 14.4 6 22.2
WHO grade 260 213
I 81 31.2 12 14.8 0.244 10 4.7 4 40.0 0.018
II 126 48.5 27 21.4 116 54.5 21 18.1
III 53 20.4 14 26.4 87 40.8 30 34.5
pT stage 342 218
pT1 218 63.7 51 23.4 0.227 109 50.0 29 26.6 0.973
pT2 98 28.7 14 14.3 91 41.7 23 25.3
pT3 12 3.5 1 8.3 10 4.6 2 20.0
pT4 14 4.1 3 21.4 8 3.7 2 25.0
Lymph node metastasis 322 217
pN0 205 63.7 38 18.5 0.538 129 59.4 31 24.0 0.590
pN1 117 36.3 25 21.4 88 40.6 24 27.3
Metastasis 341 214
M0 330 96.8 68 20.6 0.350 205 95.8 50 24.4 0.543
M1 11 3.2 1 9.1 9 4.2 3 33.3
Recurrence 345 208
no 316 91.6 67 21.2 0.065 161 77.4 40 24.8 0.211
yes 29 8.4 2 6.9 47 22.6 16 34.0
ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma. Numbers in bold indicate statistically significant P values.
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the genes differentially expressed by PLA2G7 im-
pairment. In accordance with earlier functional stud-
ies in prostate cancer cells [20], in transiently
silenced PLA2G7 siRNA transfected breast cancer
cells, the gene expression profiling highlighted the
effect of PLA2G7 on proliferation (cell cycle) and
apoptosis in addition to cell motion and adhesion
(supplementary material, Table S1). However, func-
tional cell viability and apoptosis assays with siRNA
treated MDA-468 breast cancer cells showed only a
minor decrease in cell viability at the 48 hours time
point (supplementary material, Figure S2B). Interest-
ingly, the results from genome-wide gene expression
profiling using MDA-468/PLA2G7- cells indicated
that PLA2G7 silencing decreases the expression of
genes associated with regulation of cell migration,
epithelial cell differentiation and EMT (Table 2).
Supporting the role of PLA2G7 in the regulation of
EMT as well as migration and invasion, PLA2G7
impairment induced gene expression changes
associated with IL-17A (interleukin 17A), Notch and
oncostatin M signalling. These processes have all
been previously associated with tumour metastasis or
EMT [38–42].
Validation of the effect of PLA2G7 impairment
on vimentin, E-cadherin and EGFR expression
Two major hallmarks of EMT are the loss of expres-
sion of the epithelial cell adhesion molecule E-
cadherin and gain of expression of the major mesen-
chymal cell cytoskeletal component vimentin. To
validate the role of PLA2G7 in EMT, MDA-468/
PLA2G7- cells were analysed for vimentin and E-
cadherin protein expression. The results indicated
clearly reduced vimentin and increased E-cadherin
protein levels (Figure 4A). In addition, immuno-
fluorescence staining of MDA-468/PLA2G7- cells
showed a clear decrease in vimentin staining inten-
sity in comparison to the corresponding control (Fig-
ure 4B).
Figure 3. PLA2G7 mRNA is highly expressed in triple negative
breast cancer cell lines. (A) PLA2G7 mRNA expression in oestro-
gen receptor positive and oestrogen receptor negative breast
cancer cell lines. (B) Validation of stable PLA2G7 gene silencing
in MDA-MB-468 breast cancer cells at the mRNA level.
Table 2. The effect of stable PLA2G7 silencing on gene expres-
sion profile in MDA-MB-468 breast cancer cells
Down (n5 19)
Biological processes P value
Epithelial cell differentiation 6.3E-3
Regulation of cell migration 9.4E-3
Epidermis development 1.1E-2
Regulation of cell motion 1.2E-2
Ectoderm development 1.3E-2
Canonical Pathways
Bile Acid Biosynthesis, Neutral Pathway 1.28E-2
Regulation of the Epithelial-Mesenchymal
Transition Pathway
1.36E-2
Methylglyoxal Degradation III 1.48E-2
IL-17A Signalling in Gastric Cells 2.45E-2
Notch Signalling 3.7E-2
Up (n5 39)
Biological processes
Immune response 2.5E-3
Canonical Pathways P value
Interferon Signalling 1.35E-13
Role of Pattern Recognition Receptors in
Recognition of Bacteria and Viruses
2.34E-5
Activation of IRF by Cytosolic Pattern
Recognition Receptors
1.83E-4
Oncostatin M Signalling 1.63E-3
Role of IL-17A in Psoriasis 2.26E-2
The functional gene ontology and pathway annotations were analysed for
the sets of uniformly differentially expressed genes (FC >1.5 or FC <0.666)
in response to two shRNAs. The analysis was conducted using DAVID Bioin-
formatics Resources and Ingenuity Pathway Analysis software
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Figure 4. PLA2G7 impairment decreases the protein expression of vimentin and increases the protein expression of E-cadherin. (A)
The effect of stable PLA2G7 silencing on vimentin and E-cadherin protein expression in MDA-MB-468 cells. b-actin expression was
used as an endogenous control. (B) Immunofluorescence staining of MDA-MB-468 cells without (shScrambled) or with stable PLA2G7
silencing (shPLA2G7) using vimentin antibody (red). DAPI staining (blue) was used to visualize nuclei. 633 objective magnification.
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Figure 5. PLA2G7 impairment reduces breast cancer cell invasion. (A) The effect of stable PLA2G7 silencing on MDA-MB-468 cell
motility in wound healing invasion assay at 12, 24 and 48 hours after wound scratch. The relative wound closure effect was calcu-
lated as wound confluence in comparison to shScrambled control. (B) Wound closure at 48 hours in comparison to 0 hours. Scale
bar5 300 mm. * p <0.05; ** p <0.01; *** p <0.001.
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Figure 6. Relative PLA2G7 mRNA expression in non-malignant and malignant breast, colon, kidney, liver and lung tissue samples
based on TissueScanTM Cancer Survey cDNA panel. M, metastasis; S, sarcomatoid.
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Epidermal growth factor receptor (EGFR) is known
to be frequently overexpressed and suggested as a
potential drug target in aggressive TNBCs [43,44]. In
the current study, gene expression analysis suggested
PLA2G7 as a regulator of EGFR expression in
MDA-468 breast cancer cells expressing EGFR at
high level. Western blot analysis of EGFR showed a
significant decrease in protein expression in response
to stable PLA2G7 silencing (supplementary material,
Figure S3).
Analysis of the effect of PLA2G7 impairment
on breast cancer cell invasion
To validate the putative regulatory role of PLA2G7
on breast cancer cell migration and invasion, a
wound healing invasion assay was performed with
MDA-468/PLA2G7- cells. The results showed that
stable PLA2G7 knockdown significantly reduced cell
invasion in comparison to scrambled control at 12,
24 and 48 hours (Figure 5A and B). To confirm that
the effect was not due to changes in cell viability the
effect of stable PLA2G7 silencing on cell viability
was studied (supplementary material, Figure S4). In
accordance with the experiments conducted with
PLA2G7 siRNA transfected MDA-MB-468 cells
(supplementary material, Figure S2B) stable PLA2G7
knockdown only moderately affected MDA-468 cell
viability thus confirming that the effect on cell inva-
sion was not due to reduced cell viability.
PLA2G7 mRNA expression in cancers
of various origins
The expression of PLA2G7 mRNA was further ana-
lysed in a cDNA tumour panel consisting of 65 pri-
mary and 7 metastatic tumour samples as well as 24
non-malignant tissue samples derived from 8 differ-
ent primary organs. Interestingly, the results from
breast, colon, kidney, liver and lung derived samples
showed the highest PLA2G7 expression in the
aggressive and metastatic cancer samples (Figure
6A–E). In ovarian cancer samples, no similar pattern
was seen (supplementary material, Figure S5A). In
accordance with earlier reports [20], the prostate can-
cer sample with the highest expression was the only
true cancer sample in the set (supplementary mate-
rial, Figure S5B). Surprisingly, in thyroid samples
the expression pattern was the opposite and normal
tissues showed higher PLA2G7 expression than
tumour tissues (supplementary material, Figure S5C).
Discussion
Breast cancer is the most frequent cancer in women
worldwide and the leading cause of cancer-related
deaths in women due to distinct cancer subtypes
associated with aggressive progression [1–4]. Here,
we evaluated the expression pattern of PLA2G7 in
breast cancer and investigated the molecular proc-
esses regulated by PLA2G7 in cultured breast cancer
cells.
The results from three independent clinical breast
cancer sample sets showed that PLA2G7 is highly
expressed in hormone receptor negative breast can-
cers. Analysis of transcriptomic data indicated a sig-
nificant association between high PLA2G7 mRNA
expression and poor prognosis in primary breast can-
cer samples. However, the association between high
PLA2G7 protein expression and unfavourable disease
outcome was not seen at the protein level in samples
derived from primary breast cancers. Surprisingly,
when evaluating the protein expression of PLA2G7
in the lymph node metastases, high PLA2G7 protein
expression was significantly associated with poor
prognosis. The reason for the inconsistent results in
survival analyses of primary breast cancer samples
using either PLA2G7 mRNA or protein expression
remain to be investigated. The qRT-PCR primers and
antibody used for evaluation of PLA2G7 expression
detect both of the transcripts listed in the current
release of the Ensembl database [45]. It can be
hypothesised that the results may be affected by pos-
sible PLA2G7 protein secretion or the expression of
PLA2G7 by stromal and inflammatory cells present
in the samples. However, the association between
high PLA2G7 expression and poor prognosis using
samples from lymph node metastases was acquired
using the protein expression of PLA2G7 only in the
tumour cells, supporting the role for PLA2G7 in can-
cer progression. Furthermore, PLA2G7 was also
highly expressed in metastatic or aggressive tumours
derived from cancers of other origins, indicating a
wider range of significance in cancer progression.
However, although high PLA2G7 expression associ-
ates with aggressive tumours and metastasis in many
tissues, the results were opposite in thyroid tissue,
suggesting that the role of PLA2G7 is multifaceted
and dependent on the nature of the disease and bio-
logical context.
To gain biological insights into the role of
PLA2G7 in breast cancer we performed functional
studies with breast cancer cells and identified a regu-
latory link between PLA2G7 and metastasis-enabling
EMT. The genome-wide gene expression profile
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indicated that PLA2G7 impairment altered IL-17A
(interleukin 17A), Notch and oncostatin M signalling,
supporting the role of PLA2G7 in the regulation of
EMT as well as migration and invasion. The pro-
inflammatory cytokine IL-17A has recently emerged
as a critical promoter of breast cancer metastasis,
chemoresistance, angiogenesis as well as cell prolif-
eration, whereas Notch signalling has been associated
with the activation of EMT in cancer cells [38–42].
Furthermore, inhibition of Notch signalling causes
growth arrest and inhibition of EMT in both breast
cancer stem cells and breast cancer cells [46]. Cyto-
kine oncostatin M has been associated with poor out-
come in breast cancer [47]. In addition to regulating
oestrogen receptor expression and breast cancer
metastasis to bone, oncostatin M has been reported to
mediate mesenchymal and stem cell-like differentia-
tion in breast cancer [47–49].
The effect of PLA2G7 depletion on the protein levels
of key EMT regulators, vimentin and E-cadherin as
well as the invasive phenotype was then monitored in
cultured breast cancer cells expressing PLA2G7 at high
level. The MDA-468 and BT-549 cell lines were
derived from aggressive triple-negative breast tumours
harbouring inactivating mutations in tumour suppressor
genes PTEN, RB1 and TP53 [50]. Mutations in TP53
are found in the majority of TNBCs and targeted dele-
tion of both Trp53 and Rb1 in mouse mammary stem
progenitor cells has been reported to induce aggressive
EMT-type mammary tumours [51–53]. Inhibition of
PLA2G7 expression resulted in decreased expression of
vimentin, increased expression of E-cadherin as well as
reduced cell invasion. The cytoplasmic intermediate fil-
ament protein vimentin is a central marker of EMT in
cancer. Vimentin is expressed in neoplastic breast epi-
thelial cells with metastatic properties as well as in
aggressive and metastatic clinical breast cancers, sup-
porting the association between PLA2G7 and aggressive
disease in breast cancer [14–16]. Furthermore, these
results indicate that PLA2G7 is required for cytoskeletal
alterations enabling cell migration and EMT and high-
light a significant role for PLA2G7 in breast cancer
metastasis. Regulators of EMT have been recently sug-
gested as major therapeutic targets of aggressive and
metastatic breast cancers, including triple negative
breast cancers (TNBC) [5–9,12]. Further studies are
needed to understand the mechanisms behind the ability
of PLA2G7 to regulate EMT and invasion in more
detail.
In addition to regulating EMT and invasion, PLA2G7
impairment was found to inhibit EGFR expression in
vitro. Although recent results from clinical trials study-
ing the combinatorial effect of monoclonal anti-EGFR
antibody cetuximab and carboplatin or cisplatin in the
treatment of TNBC have not been successful, combin-
ing different therapies has been suggested as a neces-
sary step to reach significant therapeutic progress
[54–59]. Interestingly, darapladib, a novel PLA2G7
inhibitor, has recently been under intensive research in
the area of cardiovascular diseases. In addition, lipid-
lowering statins are known to reduce PLA2G7 activity
in plasma, atherosclerotic plaques and cultured prostate
cancer cells [20,25,60,61]. Thus, although the first
phase III trials with darapladib did not produce much
anticipated promising results in the treatment of chronic
coronary heart disease, pharmacologically well-studied
and well-known molecules inhibiting PLA2G7, such as
darapladib and statins, could be readily translated to in
vivo preclinical studies and clinical trials also in the
area of oncology. Our results propose a possible benefi-
cial effect from the combination of PLA2G7 inhibition
with other therapies (ie EGFR targeted therapy) in
advanced breast cancer.
In conclusion, results from this study propose
PLA2G7 as an EMT and metastasis-promoting en-
zyme in a subset of breast cancers and link the exp-
ression of PLA2G7 with hormone receptor negativity
and poor prognosis especially in metastatic breast
cancer. Furthermore, in addition to breast and pros-
tate cancer, results from this study also suggest a
possible association between high PLA2G7 expres-
sion and metastasis in four other malignancies;
namely colon, kidney, liver and lung cancer. Recent
studies further link PLA2G7 with nasopharyngeal car-
cinoma invasiveness and early relapse in ovarian can-
cer [62,63]. Thus, these results present a rationale for
further exploring the role of PLA2G7 in cancer pro-
gression and the putative potential of PLA2G7 tar-
geted therapy in cancer management.
Acknowledgements
We thank Sinikka Kollanus for performing immunohis-
tochemical staining and Taina Korpela for excellent
technical assistance. We thank the Finnish DNA Micro-
array Centre for performing microarray and TaqMan
qRT-PCR analysis, and Vidal Fey as well as Arho
Virkki for the normalisation of gene expression analysis
results. John-Patrick Mpindi is acknowledged for help
in bioinformatics analyses from clinical sample data.
This work was supported by Cancer Organizations of
Finland, Sigrid Juselius Foundation, TIME collabora-
tive project, Maud Kuistila Memorial Foundation, K.
Albin Johanssons Stiftelse, Research Foundation for
Clinical Chemistry, Finnish Cultural Foundation and
the Academy of Finland.
PLA2G7 in breast cancer 135
VC 2017 The Authors The Journal of Pathology: Clinical Research published by The Pathological
Society of Great Britain and Ireland and John Wiley & Sons Ltd
J Path: Clin Res April 2017; 3: 123–138
Author contributions
Conceived and designed the experiments: LL, PV,
KI. Performed the experiments: LL, PV. Analysed
the data: LL, PV, HW, HH, PK. Contributed rea-
gents/materials/analysis tools: HW, KP, VM, AK, KI,
OK, OC. Wrote the paper: LL, PV, KI. All authors
reviewed the manuscript and had final approval of
the submitted version.
References
1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics,
2012. CA: A Cancer Journal for Clinicians 2015; 65: 87–108.
2. Lang JE, Wecsler JS, Press MF, et al. Molecular markers for
breast cancer diagnosis, prognosis and targeted therapy. J Surg
Oncol 2015; 111: 81–90.
3. Oakman C, Viale G, Di Leo A. Management of triple negative
breast cancer. Breast (Edinburgh, Scotland) 2010; 19: 312–321.
4. Woodward WA, Strom EA, Tucker SL, et al. Changes in the
2003 American Joint Committee on Cancer staging for breast
cancer dramatically affect stage-specific survival. Journal of Clin-
ical Oncology 2003; 21: 3244–3248.
5. Gupta GP, Massague J. Cancer metastasis: building a framework.
Cell 2006; 127: 679–695.
6. Jeong H, Ryu Y, An J, et al. Epithelial-mesenchymal transition
in breast cancer correlates with high histological grade and triple-
negative phenotype. Histopathology 2012; 60: E87–E95.
7. Sarrio D, Rodriguez-Pinilla S, Hardisson D, et al. Epithelial-mes-
enchymal transition in breast cancer relates to the basal-like phe-
notype. Cancer Res 2008; 68: 989–997.
8. Yamashita N, Tokunaga E, Kitao H, et al. Vimentin as a poor
prognostic factor for triple-negative breast cancer. J Cancer Res
Clin Oncol 2013; 139: 739–746.
9. Zagouri F, Bago-Horvath Z, R€ossler F, et al. High MET expres-
sion is an adverse prognostic factor in patients with triple-
negative breast cancer. Br J Cancer 2013; 108: 1100–1105.
10. Gavert N, Ben-Ze’ev A. Epithelial-mesenchymal transition and
the invasive potential of tumours. Trends Mol Med 2008; 14:
199–209.
11. Mallini P, Lennard T, Kirby J, et al. Epithelial-to-mesenchymal
transition: what is the impact on breast cancer stem cells and
drug resistance. Cancer Treat Rev 2014; 40: 341–348.
12. Tiwari N, Tiwari VK, Waldmeier L, et al. Sox4 is a master regu-
lator of epithelial-mesenchymal transition by controlling Ezh2
expression and epigenetic reprogramming. Cancer Cell 2013; 23:
768–783.
13. Chu YW, Runyan RB, Oshima RG, et al. Expression of complete
keratin filaments in mouse L cells augments cell migration and
invasion. Proc Natl Acad Sci U S A 1993; 90: 4261–4265.
14. Thompson EW, Paik S, Br~A1=4Nner N, et al. Association of
increased basement membrane invasiveness with absence of
estrogen receptor and expression of vimentin in human breast
cancer cell lines. J Cell Physiol 1992; 150: 534–544.
15. Zajchowski DA, Bartholdi MF, Gong Y, et al. Identification of
gene expression profiles that predict the aggressive behavior of
breast cancer cells. Cancer Res 2001; 61: 5168–5178.
16. Domagala W, Lasota J, Bartkowiak J, et al. Vimentin is preferen-
tially expressed in human breast carcinomas with low estrogen
receptor and high Ki-67 growth fraction. Am J Pathol 1990; 136:
219–227.
17. Sabo E, Miselevich I, Bejar J, et al. The role of vimentin expres-
sion in predicting the long-term outcome of patients with local-
ized renal cell carcinoma. Br J Urol 1997; 80: 864–868.
18. Gilles C, Polette M, Piette J, et al. Vimentin expression in cervi-
cal carcinomas: association with invasive and migratory potential.
J Pathol 1996; 180: 175–180.
19. Stafforini DM. Biology of platelet-activating factor acetylhydro-
lase (PAF-AH, lipoprotein associated phospholipase A2). Cardio-
vasc Drugs Ther 2009; 23: 73–83.
20. Vainio P, Lehtinen L, Mirtti T, et al. Phospholipase PLA2G7,
associated with aggressive prostate cancer, promotes prostate can-
cer cell migration and invasion and is inhibited by statins. Onco-
target 2011; 2: 1176–1190.
21. Vainio P, Gupta S, Ketola K, et al. Arachidonic acid pathway
members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as
putative novel therapeutic targets in prostate cancer. Am J Pathol
2011; 178: 525–536.
22. McMurray HR, Sampson ER, Compitello G, et al. Synergistic
response to oncogenic mutations defines gene class critical to
cancer phenotype. Nature 2008; 453: 1112–1116.
23. Xu C, Reichert EC, Nakano T, et al. Deficiency of phospholipase
A2 group 7 decreases intestinal polyposis and colon tumourigene-
sis in Apc(Min/1) mice. Cancer Res 2013; 73: 2806–2816.
24. May HT, Horne BD, Anderson JL, et al. Lipoprotein-associated
phospholipase A2 independently predicts the angiographic diag-
nosis of coronary artery disease and coronary death. Am Heart J
2006; 152: 997–1003.
25. O’Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-
associated phospholipase A2 and its association with cardiovascu-
lar outcomes in patients with acute coronary syndromes in the
PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and
Infection Therapy-Thrombolysis In Myocardial Infarction). Circu-
lation 2006; 113: 1745–1752.
26. Oei HS, van der Meer IM, Hofman A, et al. Lipoprotein-associ-
ated phospholipase A2 activity is associated with risk of coronary
heart disease and ischemic stroke: the Rotterdam Study. Circula-
tion 2005; 111: 570.
27. Packard CJ, O’reilly DS, Caslake MJ, et al. Lipoprotein-associ-
ated phospholipase A2 as an independent predictor of coronary
heart disease. West of Scotland Coronary Prevention Study
Group. N Engl J Med 2000; 343: 1148–1155.
28. Wilensky RL, Shi Y, Mohler ER, et al. Inhibition of lipoprotein-
associated phospholipase A2 reduces complex coronary athero-
sclerotic plaque development. Nat Med 2008; 14: 1059–1066.
29. Serruys PW, Garcıa-Garcıa HM, Buszman P, et al. Effects of the
direct lipoprotein-associated phospholipase A(2) inhibitor darapla-
dib on human coronary atherosclerotic plaque. Circulation 2008;
118: 1172–1182.
30. Kilpinen S, Autio R, Ojala K, et al. Systematic bioinformatic
analysis of expression levels of 17,330 human genes across 9,783
136 L Lehtinen et al
VC 2017 The Authors The Journal of Pathology: Clinical Research published by The Pathological
Society of Great Britain and Ireland and John Wiley & Sons Ltd
J Path: Clin Res April 2017; 3: 123–138
samples from 175 types of healthy and pathological tissues.
Genome Biol 2008; 9: R139–R139.
31. Lehtinen L, Vainio P, Wikman H, et al. 15-Hydroxyprostaglandin
dehydrogenase associates with poor prognosis in breast cancer,
induces epithelial-mesenchymal transition, and promotes cell
migration in cultured breast cancer cells. J Pathol 2012; 226:
674–686.
32. Alarmo E, Huhtala H, Korhonen T, et al. Bone morphogenetic
protein 4 expression in multiple normal and tumour tissues
reveals its importance beyond development. Modern Pathology
2013; 26: 10–21.
33. Pollari S, Kakonen SM, Edgren H, et al. Enhanced serine produc-
tion by bone metastatic breast cancer cells stimulates osteoclasto-
genesis. Breast Cancer Res Treat 2011; 125: 421–430.
34. Huang DW, Sherman BT, Lempicki RA. Systematic and integra-
tive analysis of large gene lists using DAVID bioinformatics
resources. Nature Protocols 2009; 4: 44–57.
35. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrich-
ment tools: paths toward the comprehensive functional analysis
of large gene lists. Nucleic Acids Res 2009; 37: 1–13.
36. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrich-
ment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci U S A
2005; 102: 15545–15550.
37. Mootha VK, Lindgren CM, Eriksson K, et al. PGC-1alpha-
responsive genes involved in oxidative phosphorylation are coor-
dinately downregulated in human diabetes. Nat Genet 2003; 34:
267–273.
38. Brabletz S, Bajdak K, Meidhof S, et al. The ZEB1/miR-200 feed-
back loop controls Notch signalling in cancer cells. Embo J
2011; 30: 770–782.
39. Du J, Xu K, Fang L, et al. Interleukin-17, produced by lympho-
cytes, promotes tumour growth and angiogenesis in a mouse
model of breast cancer. Mol Med Rep 2012; 6: 1099–1102.
40. Benevides L, Cardoso CRB, Tiezzi DG, et al. Enrichment of reg-
ulatory T cells in invasive breast tumour correlates with the
upregulation of IL-17A expression and invasiveness of the
tumour. Eur J Immunol 2013; 43: 1518–1528.
41. Cochaud S, Giustiniani J, Thomas C, et al. IL-17A is produced
by breast cancer TILs and promotes chemoresistance and prolifer-
ation through ERK1/2. Sci Rep 2013; 3: 3456–3456.
42. Roy LD, Sahraei M, Schettini JL, et al. Systemic neutralization
of IL-17A significantly reduces breast cancer associated metasta-
sis in arthritic mice by reducing CXCL12/SDF-1 expression in
the metastatic niches. BMC Cancer 2014; 14: 225.
43. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of
the basal-like subtype of invasive breast carcinoma. Modern
Pathol 2006; 19: 264–271.
44. Liu D, He J, Yuan Z, et al. EGFR expression correlates with
decreased disease-free survival in triple-negative breast cancer: a
retrospective analysis based on a tissue microarray. Med Oncol
2012; 29: 401–405.
45. Cunningham F, Amode MR, Barrell D, et al. Ensembl 2015.
Nucleic Acids Res 2014; 43: D662–D669.
46. Suman S, Das TP, Damodaran C. Silencing NOTCH signaling
causes growth arrest in both breast cancer stem cells and breast
cancer cells. Br J Cancer 2013; 109: 2587–2596.
47. West NR, Murphy LC, Watson PH. Oncostatin M suppresses
oestrogen receptor-a expression and is associated with poor out-
come in human breast cancer. Endocr Relat Cancer 2012; 19:
181–195.
48. Bolin C, Tawara K, Sutherland C, et al. Oncostatin M promotes
mammary tumour metastasis to bone and osteolytic bone degra-
dation. Genes Cancer 2012; 3: 117–130.
49. West NR, Murray JI, Watson PH. Oncostatin-M promotes phe-
notypic changes associated with mesenchymal and stem cell-
like differentiation in breast cancer. Oncogene 2014; 33: 1485–
1494.
50. Lehmann BD, Bauer JA, Chen X, et al. Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest 2011; 121: 2750–
2767.
51. Langerod A, Zhao H, Borgan O, et al. TP53 mutation status and
gene expression profiles are powerful prognostic markers of
breast cancer. Breast Cancer Res 2007; 9: R30.
52. Jiang Z, Deng T, Jones R, et al. Rb deletion in mouse mam-
mary progenitors induces luminal-B or basal-like/EMT tumour
subtypes depending on p53 status. J Clin Invest 2010; 120:
3296–3309.
53. Dumay A, Feugeas JP, Wittmer E, et al. Distinct tumour protein
p53 mutants in breast cancer subgroups. Int J Cancer 2013; 132:
1227–1231.
54. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: random-
ized phase II study of cetuximab in combination with carboplatin
in stage IV triple-negative breast cancer. J Clin Oncol 2012;30:
2615–2623.
55. Baselga J, Gomez P, Greil R, et al. Randomized phase II study
of the anti-epidermal growth factor receptor monoclonal antibody
cetuximab with cisplatin versus cisplatin alone in patients with
metastatic triple-negative breast cancer. J Clin Oncol 2013; 31:
2586–2592.
56. Kim EJ, Jeong J, Bae S, et al. mTOR inhibitors radiosensitize
PTEN-deficient non-small-cell lung cancer cells harboring an
EGFR activating mutation by inducing autophagy. J Cell Bio-
chem 2013; 114: 1248–1256.
57. Koumangoye RB, Nangami GN, Thompson PD, et al. Reduced
annexin A6 expression promotes the degradation of activated epi-
dermal growth factor receptor and sensitizes invasive breast can-
cer cells to EGFR-targeted tyrosine kinase inhibitors. Molecular
Cancer 2013; 12: 167–167.
58. Morrison G, Fu X, Shea M, et al. Therapeutic potential of the
dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine
resistance. Breast Cancer Res Treat 2014; 144: 263–272.
59. Brand TM, Iida M, Dunn EF, et al. Nuclear epidermal growth
factor receptor is a functional molecular target in triple-negative
breast cancer. Molecular Cancer Therapeutics 2014; 13: 1356–
1368.
60. Schaefer EJ, McNamara JR, Asztalos BF, et al. Effects of ator-
vastatin versus other statins on fasting and postprandial C-
reactive protein and lipoprotein-associated phospholipase A2 in
patients with coronary heart disease versus control subjects. Am J
Cardiol 2005; 95: 1025–1032.
61. Racherla S, Arora R. Utility of Lp-PLA2 in lipid-lowering ther-
apy. Am J Ther 2012; 19: 115–120.
PLA2G7 in breast cancer 137
VC 2017 The Authors The Journal of Pathology: Clinical Research published by The Pathological
Society of Great Britain and Ireland and John Wiley & Sons Ltd
J Path: Clin Res April 2017; 3: 123–138
62. Reinartz S, Finkernagel F, Adhikary T, et al. A transcriptome-
based global map of signaling pathways in the ovarian cancer
microenvironment associated with clinical outcome. Genome Biol
2016; 17: 108.
63. Low HB, Png CW, Li C, et al. Monocyte-derived factors includ-
ing PLA2G7 induced by macrophage-nasopharyngeal carcinoma
cell interaction promote tumour cell invasiveness. Oncotarget
2016; 7: 55473–55490.
SUPPLEMENTARY MATERIAL ONLINE
Supplementary figure legends
Table S1. The effect of transient PLA2G7 silencing on breast cancer cell gene expression profile
Figure S1. The mRNA co-expression pattern of PLA2G7 and HER2/neu (ERBB2) in breast cancer samples (n 5 957)
Figure S2. (A) Validation of transient PLA2G7 gene silencing in MDA-MB-468 breast cancer cells at the mRNA level. (B) The effect of 48 h
PLA2G7 and KIF11 silencing on MDA-MB-468 cell viability. (C) The effect of 48 h PLA2G7 and KIF11 silencing on induction of apoptosis
in MDA-MB-468 cells
Figure S3. The effect of stable PLA2G7 silencing on EGFR protein expression in MDA-MB-468 cells. actin expression was used as an endog-
enous control
Figure S4. The effect of stable PLA2G7 silencing and shScrambled expression on MDA-MB-468 cell viability at 48 h after plating equal num-
bers of cells
Figure S5. Relative PLA2G7 mRNA expression in non-malignant and malignant ovarian, prostate and thyroid tissue samples based on TissueS-
canTM Cancer Survey cDNA panel
138 L Lehtinen et al
VC 2017 The Authors The Journal of Pathology: Clinical Research published by The Pathological
Society of Great Britain and Ireland and John Wiley & Sons Ltd
J Path: Clin Res April 2017; 3: 123–138
